The stock decreased 2.04% or $0.08 during the last trading session, reaching $3.84. About 7,424 shares traded. ADMA Biologics, Inc. (NASDAQ:ADMA) has declined 37.56% since March 5, 2017 and is downtrending. It has underperformed by 54.26% the S&P500.
Congress Asset Management Company increased its stake in Colgate (CL) by 3.26% based on its latest 2017Q3 regulatory filing with the SEC. 3,189,293 shares of the stock traded hands, compared to its average volume of 3,916,903. Vanguard Group Inc. now owns 67,875,384 shares of the company's stock valued at $5,031,602,000 after acquiring an additional 1,621,392 shares in the last quarter. Vantage Investment Partners Llc who had been investing in Colgate for a number of months, seems to be bullish on the $60.63 billion market cap company. First Manhattan Company who had been investing in Colgate Palmolive Co for a number of months, seems to be less bullish one the $61.04B market cap company. It has underperformed by 35.50% the S&P500.
Among 7 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Vodafone Group PLC (ADR) had 15 analyst reports since October 19, 2015 according to SRatingsIntel. HSBC downgraded Vodafone Group Plc (NASDAQ:VOD) on Tuesday, January 17 to "Hold" rating. Stifel Nicolaus maintained the stock with "Hold" rating in Friday, October 27 report. Bank of America downgraded Vodafone Group Plc (NASDAQ:VOD) on Wednesday, January 25 to "Neutral" rating. The stock has "Buy" rating by SunTrust on Wednesday, October 11. The stock has "Equal-Weight" rating by Barclays Capital on Monday, March 21. The company was upgraded on Monday, September 12 by Bank of America. Insiders own 1.02% of the company's stock. Krilogy Financial LLC lifted its position in Colgate-Palmolive by 23.0% during the 2nd quarter.
Since December 13, 2017, it had 0 buys, and 19 insider sales for $31.54 million activity.
In related news, VP Henning I. Jakobsen sold 36,215 shares of the company's stock in a transaction dated Monday, February 5th. 1,524 shares valued at $106,939 were sold by HUSTON JOHN J on Tuesday, February 20. Company insiders own 1.02% of the company's stock. The insider Dolan Victoria L sold $120,830. On Tuesday, February 20 Marsili Daniel B sold $399,530 worth of Colgate-Palmolive Company (NYSE:CL) or 5,692 shares. Colgate-Palmolive Company (NYSE:CL) has risen 6.23% since March 5, 2017 and is uptrending. (NASDAQ:ADMA). Consonance Management Lp accumulated 1.27M shares. Jackson Grant Investment Advisers Inc. increased its holdings in Colgate-Palmolive by 0.5% during the second quarter.
Investors sentiment is 0.9 in 2017 Q3. Its the same as in 2017Q2.
Several other hedge funds and other institutional investors have also recently bought and sold shares of CL. Jacobi Capital Management LLC raised its stake in shares of Colgate-Palmolive by 125.5% during the 3rd quarter. Blackrock accumulated 0.19% or 51.65 million shares. Hall Laurie J Trustee holds 0.15% or 3,200 shares in its portfolio. Amp Capital Investors has 594,665 shares for 0.24% of their portfolio. Teacher Retirement Of Texas reported 0% in Portola Pharmaceuticals, Inc. Cibc Asset Management Incorporated holds 0.05% or 104,402 shares in its portfolio. The Bailard Inc holds 74,873 shares with $5.45 million value, up from 69,191 last quarter. Schroder Investment Grp Inc has invested 0.12% in Colgate-Palmolive Company (NYSE:CL). It improved, as 4 investors sold ADMA shares while 3 reduced holdings. Beck Mack & Oliver Limited Liability Co stated it has 55,449 shares or 0.13% of all its holdings. 100 were accumulated by Shine Inv Advisory Service Inc. Moreover, Piedmont Investment Ltd Liability Corporation has 0.29% invested in Colgate-Palmolive Company (NYSE:CL) for 185,860 shares. Howe And Rusling reported 7,628 shares or 0.1% of all its holdings. $346,581 worth of Colgate-Palmolive Company (NYSE:CL) shares were sold by HANCOCK ELLEN M. Finally, NorthCoast Asset Management LLC increased its stake in Colgate-Palmolive by 0.3% during the 2nd quarter.
Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, January 26th. During the same quarter last year, the firm earned $0.75 EPS. research analysts expect that Colgate-Palmolive will post 3.18 earnings per share for the current fiscal year. CL's profit will be $647.70 million for 23.56 P/E if the $0.74 EPS becomes a reality. The company reported $0.75 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.75. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. Therefore 24% are positive. Deutsche Bank assumed coverage on Colgate-Palmolive in a research report on Wednesday, December 13th. Finally, KeyCorp reissued a "hold" rating on shares of Colgate-Palmolive in a research report on Saturday, November 25th. Colgate-Palmolive now has a consensus rating of "Hold" and a consensus target price of $77.91. The company was maintained on Friday, May 26 by RBC Capital Markets. Jefferies Group restated a "hold" rating and set a $79.00 target price on shares of Colgate-Palmolive in a report on Friday, January 26th. The firm earned "Hold" rating on Tuesday, May 30 by Jefferies. The company was maintained on Friday, April 29 by UBS. The firm has "Overweight" rating by Morgan Stanley given on Monday, September 25.